Hospital Medicine Unplugged

In this episode of Hospital Medicine Unplugged, we sprint through thyroid cancer—understand the epidemiologic paradox of rising incidence but stable mortality, stage disease using modern AJCC criteria, apply ATA recurrence risk stratification, and tailor therapy from surgery and radioiodine to targeted molecular treatments.
We start with the epidemiology of thyroid carcinoma, the most common endocrine malignancy and the ninth most common cancer worldwide. In 2022 alone, there were roughly 821,000 new cases and 47,500 deaths globally. The disease shows a strong female predominance—about three quarters of cases occur in women, and the median age at diagnosis is in the early 50s. Notably, thyroid cancer is also the most common malignancy among adolescents and young adults aged 16–33 years.
One of the most striking trends is the dramatic rise in incidence over the past four decades. Global age-standardized incidence increased substantially from about 2.1 per 100,000 in 1990 to over 3.1 per 100,000 in 2017, with extremely high rates reported in countries such as South Korea, Cyprus, Ecuador, China, and Turkey. Yet mortality has remained remarkably stable at roughly 0.5 per 100,000, suggesting that much of the increase reflects overdiagnosis rather than a true surge in aggressive disease.
The driver behind this phenomenon is increased detection of small papillary thyroid cancers, often discovered incidentally during thyroid ultrasonography or cross-sectional imaging. Some studies estimate that more than 75% of thyroid cancers globally may represent overdiagnosis, particularly in high-income countries where imaging is widespread. Encouragingly, incidence rates have begun to plateau or decline in some regions following guideline changes discouraging unnecessary biopsy and treatment of very small nodules.
Next, we turn to staging, which guides prognosis and management. The AJCC 8th edition TNM staging system introduced an important shift by raising the prognostic age cutoff from 45 to 55 years. This reflects the excellent survival outcomes seen in younger patients.
For patients younger than 55 years, staging is remarkably simple:• Stage I: any tumor size, any lymph node status, no distant metastasis• Stage II: distant metastasis present
This simplified system reflects the outstanding prognosis in younger individuals, with more than 98% survival regardless of tumor characteristics.
For patients 55 years and older, staging becomes more detailed and incorporates tumor size, lymph node involvement, and extrathyroidal extension. Importantly, the 8th edition refined the definition of extrathyroidal extension so that only gross invasion of strap muscles qualifies for T3b staging, which has downstaged many patients and improved prognostic accuracy.
However, staging alone does not fully predict recurrence. That role belongs to the American Thyroid Association (ATA) risk stratification system, which categorizes patients as low, intermediate, or high risk of recurrence.
Approximate recurrence rates are:• Low risk: ~1.5%• Intermediate risk: ~5% overall• High risk: ~25%
A key innovation in ATA management is dynamic risk stratification, where risk is continuously updated based on response to therapy.
Response categories include:• Excellent response: ~4.7% recurrence risk• Indeterminate response: ~17% recurrence• Biochemically incomplete: ~58% recurrence• Structurally incomplete: ~84% recurrence
This dynamic approach allows clinicians to de-escalate surveillance and treatment for patients who demonstrate excellent responses over time.
At the molecular level, thyroid cancer has a remarkably simple genomic landscape, dominated by mutations activating the MAPK signaling pathway.
The most common driver mutation is BRAF V600E, found in about 60% of papillary thyroid cancers. This mutation is associated with classic and tall-cell variants, increased lymph node metastases, and reduced responsiveness to radioactive iodine due to suppression of the sodium-iodide symporter.
Another important group includes RAS mutations, seen in follicular thyroid cancers and follicular-variant papillary carcinomas. These tumors often demonstrate vascular invasion but retain better responsiveness to radioactive iodine therapy.
Chromosomal rearrangements also play a role. RET/PTC fusions are common in radiation-induced thyroid cancers and pediatric cases, while TERT promoter mutations—particularly when combined with BRAF mutations—are associated with aggressive disease and poor prognosis.
Management of differentiated thyroid cancer increasingly emphasizes risk-adapted therapy, particularly regarding radioactive iodine (RAI).
RAI can serve three purposes:• Remnant ablation after surgery• Adjuvant therapy to reduce recurrence risk• Treatment of known metastatic disease
Modern guidelines recommend avoiding routine RAI in low-risk patients, particularly those with small intrathyroidal papillary cancers ≤2 cm, negative lymph nodes, low postoperative thyroglobulin, and normal ultrasound.
RAI becomes selectively recommended when additional risk factors are present, such as tumors >4 cm, nodal metastases, lymphatic invasion, aggressive histologic variants, or elevated postoperative thyroglobulin levels.
For high-risk disease, including gross extrathyroidal extension, extensive nodal disease, or distant metastases, RAI therapy remains standard because it improves both survival and recurrence outcomes.
When thyroid cancer becomes radioiodine-refractory, systemic therapy may be required. Several targeted agents are now available.
First-line multikinase inhibitors include:• Lenvatinib, which significantly improves progression-free survival and has response rates approaching 65%• Sorafenib, with more modest response rates but proven efficacy
Second-line therapy includes cabozantinib for patients progressing after first-line agents.
Precision medicine is increasingly important. Tumors with specific driver mutations may respond dramatically to targeted therapies:
• RET fusions: treated with selpercatinib or pralsetinib, with response rates approaching 80–90%• BRAF V600E: targeted with dabrafenib plus trametinib, particularly in anaplastic thyroid cancer• NTRK fusions: treated with larotrectinib or entrectinib, with high response rates
Despite these advances, systemic therapy is not curative and often causes substantial side effects. Therefore, treatment should generally be reserved for progressive or symptomatic disease, while patients with slow-growing, asymptomatic metastases may be safely observed.
We close with the key clinical takeaways:
• Rising thyroid cancer incidence largely reflects overdiagnosis of small papillary tumors• AJCC staging predicts survival, while ATA risk stratification predicts recurrence• Dynamic response-to-therapy assessment allows individualized long-term management• Molecular drivers like BRAF, RAS, and RET shape prognosis and treatment options• Radioactive iodine is increasingly used selectively rather than routinely
Thyroid cancer illustrates a modern shift in oncology—from one-size-fits-all treatment toward precision risk-adapted care, balancing effective therapy with avoidance of unnecessary intervention.

In this episode of Hospital Medicine Unplugged, we sprint through anaphylaxis—recognize the rapid systemic reaction, understand the mast-cell storm driving shock, and deliver epinephrine immediately to prevent cardiovascular collapse.
We begin with the definition and diagnostic framework. Anaphylaxis is a severe, rapid-onset, life-threatening systemic hypersensitivity reaction. When it progresses to circulatory collapse with profound vasodilation and vascular leak, it becomes anaphylactic shock, a form of distributive shock with relative hypovolemia. Modern guidelines define anaphylaxis clinically: acute onset of illness with skin or mucosal symptoms plus respiratory compromise, hypotension, or severe gastrointestinal symptoms, or hypotension/bronchospasm after known allergen exposure—even without skin findings.
Next comes epidemiology. Anaphylaxis occurs in roughly 50–112 episodes per 100,000 person-years, and 1.6–5.1% of adults in the United States experience an episode during their lifetime. Fortunately, modern treatment has kept mortality low. Case fatality rates among emergency presentations are about 0.25–0.33%, translating to roughly 186–225 deaths per year in the United States.
Triggers vary by age. Food-induced anaphylaxis predominates in young children, while medication-induced reactions are more common in adults, especially those over age 50.
At the core of anaphylaxis lies mast-cell and basophil activation. In classic IgE-mediated type I hypersensitivity, an allergen first sensitizes the immune system, leading B cells to produce IgE antibodies that bind to high-affinity FcεRI receptors on mast cells and basophils. On re-exposure, allergen cross-linking of IgE triggers rapid cellular degranulation.
This releases a cascade of mediators including:
• Histamine and tryptase• Leukotrienes and prostaglandins• Platelet-activating factor (PAF)• Cytokines such as IL-4 and IL-6
These mediators cause vasodilation, endothelial barrier disruption, bronchoconstriction, and massive capillary leak, shifting fluid from the intravascular space to tissues. The result is hypotension, airway compromise, and multisystem dysfunction.
Not all anaphylaxis is IgE mediated. Alternative mechanisms include IgG-mediated reactions, complement activation, contact system activation, and direct mast-cell activation via MRGPRX2 receptors. Clinically, these non-IgE pathways can produce identical presentations, which is why anaphylaxis remains a clinical diagnosis rather than a laboratory one.
The most common triggers fall into three major groups:
• Foods (≈32–37%)• Medications (≈21–58%)• Insect venom (≈15–25%)
In the United States, nine foods account for over 90% of IgE-mediated food allergies: milk, egg, wheat, soy, peanuts, tree nuts, fish, shellfish, and sesame. Peanuts remain the leading cause of fatal food-related anaphylaxis.
An emerging cause is alpha-gal syndrome, a delayed meat allergy triggered by tick bites, affecting tens to hundreds of thousands of individuals in the United States.
Medications are the most common trigger in adults, particularly beta-lactam antibiotics, followed by NSAIDs, biologic agents, chemotherapy drugs, and ACE inhibitors.
Another important concept is cofactors—conditions that lower the threshold for anaphylaxis. These include exercise, alcohol, infection, menstruation, and NSAID use. A classic example is food-dependent exercise-induced anaphylaxis, where patients tolerate a food normally but develop anaphylaxis if they exercise soon after ingestion.
Diagnosis relies on clinical criteria, most commonly the NIAID/FAAN criteria. Anaphylaxis is highly likely when there is acute involvement of skin or mucosa plus respiratory compromise or hypotension, multisystem involvement after allergen exposure, or isolated hypotension after exposure to a known trigger.
Laboratory confirmation is not required in the acute setting, but serum tryptase measured 90 minutes to 4 hours after symptom onset can support the diagnosis. An increase of 1.2 × baseline plus 2 ng/mL strongly suggests mast-cell activation.
Now to the most critical step: treatment.
Epinephrine is the first-line and life-saving therapy.
It should be administered immediately intramuscularly into the mid-anterolateral thigh at a dose of:
• 0.01 mg/kg of 1 mg/mL solution• Maximum 0.3 mg in children• Maximum 0.5 mg in adults
Doses can be repeated every 5–15 minutes if symptoms persist. There are no contraindications to epinephrine in anaphylaxis—even in patients with cardiovascular disease.
Delayed epinephrine administration is the strongest modifiable risk factor for fatal anaphylaxis.
Adjunctive therapies follow epinephrine but never replace it. These include:
• High-flow oxygen• Aggressive IV crystalloid resuscitation• H1 antihistamines (diphenhydramine)• H2 blockers• Systemic corticosteroids• Bronchodilators for bronchospasm
For patients taking beta-blockers who develop refractory hypotension, glucagon may be used because it increases cyclic AMP independent of beta receptors.
Rarely, patients develop refractory anaphylactic shock, defined by persistent symptoms despite multiple epinephrine doses. Management may require IV epinephrine infusion, additional vasopressors, airway management, and aggressive fluid resuscitation. In extreme cases, methylene blue or extracorporeal life support has been used as rescue therapy.
Another important phenomenon is biphasic anaphylaxis, where symptoms recur after initial resolution without new allergen exposure. This occurs in about 5–6% of cases, typically within 10 hours.
Recommended observation periods depend on severity:
• Minimum 4 hours for uncomplicated reactions• 6–8 hours with respiratory compromise• 12–24 hours for hypotension or severe reactions
Longer monitoring is advised for patients with severe initial presentation, multiple epinephrine doses, asthma, unknown trigger, or prior biphasic reactions.
Special consideration is needed for patients on beta-blockers or ACE inhibitors, which may increase severity of reactions and blunt compensatory cardiovascular responses. These medications are not absolutely contraindicated, but management should involve shared decision-making regarding risks and benefits.
Long-term management focuses on prevention and preparedness.
All patients who experience anaphylaxis should receive:
• Epinephrine autoinjectors• Education on prompt use• Referral for allergy evaluation and trigger identification
Patients should carry two autoinjectors at all times, as repeat dosing may be required.
Additional prevention strategies include allergen avoidance, personalized emergency action plans, medical alert identification, and immunotherapy when appropriate. For example, venom immunotherapy is highly effective for Hymenoptera sting allergy, and oral immunotherapy is now available for peanut allergy.
We close with the key clinical pearls:
• Anaphylaxis is a clinical diagnosis—do not delay treatment• Epinephrine IM is the first and most important therapy• Food, medications, and insect venom are the most common triggers• Cofactors like exercise or alcohol can lower reaction thresholds• Always prescribe epinephrine autoinjectors and educate patients before discharge
Recognize the signs, inject epinephrine early, and monitor carefully—because in anaphylaxis, minutes matter and rapid treatment saves lives.

In this episode of Hospital Medicine Unplugged, we sprint through upper motor neuron (UMN) syndromes—how spasticity develops, how to separate true reflex hyperexcitability from fixed stiffness, and how to diagnose and manage major UMN diseases like PLS and hereditary spastic paraplegia.
We begin with spasticity, a defining feature of UMN injury that is not simply an immediate “release phenomenon.” Its delayed appearance after stroke or spinal cord injury points to maladaptive plasticity in both the spinal cord and brain. The core problem is loss of descending inhibitory control, with reduced corticospinal input, increased reticulospinal drive, impaired spinal inhibitory circuits, heightened alpha motor neuron excitability, and reduced postactivation depression, especially with immobilization.
Clinically, spasticity is a velocity-dependent increase in tone caused by hyperexcitable stretch reflexes. But bedside hypertonia often has two components: reflex-mediated spasticity and intrinsic soft tissue stiffness from contracture and rheologic muscle change. That distinction matters. The Modified Ashworth Scale measures overall resistance, but the Tardieu Scale better separates dynamic spasticity from fixed mechanical tightness.
We then turn to primary lateral sclerosis (PLS), the prototypical adult UMN-predominant degenerative disorder. The 2020 consensus criteria define probable PLS as 2–4 years of progressive UMN syndrome and definite PLS as more than 4 years of symptoms. That time threshold matters because shorter duration carries higher risk of later ALS conversion. Even in clinically pure PLS, minor EMG abnormalities like fasciculations or fibrillations can occur, especially with longer disease duration.
Next is hereditary spastic paraplegia (HSP), a genetically diverse disorder marked by bilateral leg spasticity, hyperreflexia, and extensor plantar responses from length-dependent corticospinal tract degeneration. HSP is classified into pure forms, where spastic paraparesis dominates, and complex forms, where additional neurologic features appear. Although SPAST (SPG4) and SPG7 are among the most common mutations, a genetic diagnosis is still achieved in only a minority of patients.
MRI is the gold standard imaging study in suspected UMN disease. Key findings include corticospinal tract T2/FLAIR hyperintensity, especially in the posterior limb of the internal capsule and cerebral peduncles, as well as the “motor band sign,” a T2/SWI hypointensity in the precentral gyrus reflecting iron deposition. Motor cortex atrophy may be even more sensitive than the physical exam for detecting UMN degeneration and can appear before overt clinical signs.
We also highlight the distinction between pseudobulbar palsy and bulbar palsy. Pseudobulbar palsy comes from bilateral corticobulbar UMN lesions and produces spastic dysarthria, brisk jaw jerk, and exaggerated gag reflex. It is often accompanied by pseudobulbar affect—uncontrollable laughing or crying out of proportion to context. In contrast, bulbar palsy reflects LMN dysfunction of cranial nerve nuclei or nerves.
Management of spasticity follows a stepwise approach. Start with physical therapy, stretching, splinting, bracing, and positioning. For focal spasticity, botulinum toxin A has the strongest evidence and is preferred because it improves tone without systemic sedation. For generalized spasticity, oral agents include baclofen, tizanidine, benzodiazepines, and dantrolene, though benefit is often limited by sedation or weakness. In severe refractory cases, intrathecal baclofen pumps provide greater efficacy at lower doses—but pump failure can cause life-threatening withdrawal.
We close with the take-home moves: recognize that spasticity is dynamic neurophysiology plus biomechanics, use MRI and timeline to refine the diagnosis, distinguish pseudobulbar from bulbar syndromes, and treat spasticity with a layered rehab-first strategy before escalating to botulinum toxin or intrathecal therapy.
UMN syndromes are about more than “increased tone”—they are disorders of descending control, adaptive failure, and progressive disability, and careful phenotyping is what turns bedside findings into precise diagnosis and treatment.

In this episode of Hospital Medicine Unplugged, we break down endovascular infections—vascular graft infections, mycotic aneurysms, CIED infections, and septic thrombophlebitis syndromes—focusing on modern epidemiology, evolving microbiology, advanced imaging, and high-yield management strategies.
We begin with epidemiology clinicians should know. Vascular graft infections occur in ~0.5–6% of vascular reconstructions, while endovascular device infections occur in ~0.2–5% of procedures, with TEVAR carrying higher infection risk than abdominal repairs. Meanwhile, cardiac implantable electronic device (CIED) infections have increased substantially, reflecting growing device use.
Next we review key microbiology. Gram-positive cocci cause most vascular graft infections, with coagulase-negative staphylococci now more common than S. aureus. MRSA is increasingly prevalent and linked to worse outcomes, while Pseudomonas aeruginosa leads among gram-negative pathogens. For mycotic aneurysms, Salmonella species remain classic causes, with rare pathogens including Listeria and Mycobacterium tuberculosis.
We then highlight important clinical syndromes.Lemierre syndrome presents with pharyngitis, internal jugular vein thrombosis, and septic emboli (often pulmonary) and is classically caused by Fusobacterium necrophorum, though MRSA and polymicrobial infections are increasingly recognized. Pylephlebitis, sometimes called the abdominal variant of Lemierre syndrome, involves septic thrombosis of the portal venous system.
Diagnosis relies heavily on advanced imaging. CTA is typically the first-line test, while 18F-FDG PET/CT provides high sensitivity (~94%) and excellent negative predictive value, especially in late graft infections. TEE remains essential for suspected CIED infection, though repeat imaging may be needed if initial studies are negative.
Management requires combined antimicrobial and procedural strategies.• ≥6 weeks of antibiotics for most vascular graft infections• Device removal for confirmed CIED infection, with early extraction improving survival• 3–6 weeks of antibiotics for Lemierre syndrome, often metronidazole plus a β-lactam, with MRSA coverage in high-risk patients• Lifelong suppressive therapy may be needed when infected devices cannot be removed
We close with key controversies and outcomes. Anticoagulation for septic thrombophlebitis remains debated, though many experts consider 6–12 weeks of therapy in selected patients. Despite advances, vascular graft infections and mycotic aneurysms carry high mortality—often exceeding 30% at one year—especially with MRSA.
Early recognition, PET/CT-guided diagnosis, aggressive antibiotics, and timely device removal remain the pillars of care for these complex infections.

In this episode of Hospital Medicine Unplugged, we sprint through delirium tremens—the most dangerous stage of alcohol withdrawal—recognize the neurochemical storm, identify high-risk patients, and treat aggressively with benzodiazepines and supportive care to prevent fatal complications.
We begin with epidemiology and why DTs matter. Delirium tremens occurs in 3–5% of hospitalized patients with alcohol withdrawal and represents the most severe manifestation of the withdrawal spectrum. The syndrome combines acute delirium—rapidly fluctuating attention and cognition—with severe autonomic hyperactivity. Historically mortality approached 15%, but with modern aggressive treatment it has fallen to about 1–4%. When death occurs, it is usually due to hyperthermia, malignant arrhythmias, withdrawal seizures, or underlying medical illness.
Next comes the neurobiology driving withdrawal. Chronic alcohol exposure forces the brain to compensate for alcohol’s depressant effects. Over time:
• NMDA glutamate receptors are upregulated• GABA-A inhibitory receptors are downregulated
While alcohol is present, its GABA-enhancing and NMDA-suppressing effects maintain balance. When alcohol is abruptly stopped, that balance collapses. The result is unopposed excitatory neurotransmission, increased glutamate signaling, reduced GABA inhibition, and massive central nervous system hyperexcitability. Additional contributors include increased norepinephrine activity, dopaminergic alterations, and calcium-mediated excitotoxicity, producing the agitation, tremor, and seizure risk characteristic of severe withdrawal.
Risk stratification is essential because not every patient with withdrawal develops delirium tremens. The strongest predictor is a prior history of DTs, which carries a likelihood ratio of roughly 2.9 for recurrence. Other important risk factors include:
• Recent withdrawal seizures, especially multiple seizures• High CIWA-Ar scores (>15) with tachycardia or hypertension• Older age (≥55 years)• Concurrent illness such as infection, trauma, electrolyte abnormalities, or liver disease• Hypokalemia and metabolic derangements
Another key concept is the kindling effect. Repeated withdrawal episodes progressively sensitize neuronal circuits, meaning each withdrawal episode tends to become more severe than the last.
The timeline of alcohol withdrawal follows a predictable pattern.
• 6–12 hours: early withdrawal—tremor, anxiety, tachycardia• 12–24 hours: alcoholic hallucinosis (visual or auditory hallucinations)• 12–48 hours: withdrawal seizures• 72–96 hours: onset of delirium tremens, typically lasting 2–3 days but up to a week
Importantly, about one-third of untreated withdrawal seizures progress to delirium tremens, making early treatment critical.
Clinically, DTs presents with severe agitation and delirium combined with autonomic instability. Key features include:
• Fluctuating confusion and disorientation• Marked agitation and psychomotor hyperactivity• Tachycardia, hypertension, fever, and diaphoresis• Coarse tremor and hyperreflexia• Vivid visual hallucinations, often insects or animals
Diagnosis is clinical—delirium occurring in the context of alcohol withdrawal. The CIWA-Ar scale helps quantify withdrawal severity, but it becomes less reliable once patients develop delirium because it depends on patient responses. In ICU settings, clinicians often switch to CAM-ICU, RASS, MINDS, or DDS scales.
Laboratory evaluation should focus on complications and reversible triggers. Important tests include:
• Electrolytes (magnesium, potassium, phosphate)• Glucose• Liver function tests• Creatine kinase for rhabdomyolysis risk
Neuroimaging should be obtained if the presentation is atypical or focal neurologic deficits are present.
Management centers on rapid sedation and physiologic stabilization.
Benzodiazepines are first-line therapy, acting as GABA-A agonists to counter the hyperexcitable brain. Two dosing strategies dominate:
• Symptom-triggered therapy, which reduces medication exposure and treatment duration• Front-loading with high doses for severe withdrawal (CIWA-Ar ≥19)
Clinicians should not fear very high benzodiazepine doses. Severe DTs may require hundreds of milligrams of diazepam per day, and case reports describe successful treatment with 260–480 mg/day.
Agent selection depends on clinical context:
• Diazepam or chlordiazepoxide – preferred long-acting agents for front-loading• Lorazepam – preferred in liver disease, since it lacks active metabolites
For benzodiazepine-refractory DTs, ICU-level therapies may be required.
Adjunctive options include:
• Phenobarbital, which enhances GABA signaling and may reduce mechanical ventilation risk• Propofol, used in intubated patients with refractory agitation• Dexmedetomidine, an α2-agonist that suppresses sympathetic overactivity while allowing arousable sedation
Antipsychotics should never be used as monotherapy, as they lower seizure threshold. They may be used only as adjuncts for severe hallucinations or agitation.
Supportive care is equally critical. One rule must never be forgotten:
Thiamine must be administered before glucose.
High-dose thiamine—500 mg IV once or twice daily for several days—prevents Wernicke encephalopathy, a devastating but preventable neurologic complication.
Other essential measures include:
• IV fluids and hydration• Aggressive correction of magnesium, potassium, and phosphate• Temperature control and frequent vital monitoring• Calm, well-lit environment with reassurance and reorientation
Patients should be admitted to the ICU when they develop delirium tremens, severe withdrawal (CIWA ≥20), refractory symptoms despite benzodiazepines, unstable vital signs, or serious comorbid illness such as pancreatitis or GI bleeding.
Complications of DTs can be dramatic and life-threatening. They include:
• Cardiac arrhythmias and myocardial ischemia• Hyperthermia• Withdrawal seizures and status epilepticus• Aspiration pneumonia• Rhabdomyolysis with acute kidney injury• Severe electrolyte disturbances, especially hypokalemia
Despite modern treatment, patients who experience DTs have significantly increased long-term mortality, with an annual mortality rate around 8%, particularly due to trauma, suicide, and other alcohol-related causes.
We close with the essential clinical pearls:
• Delirium tremens is a clinical diagnosis—treat immediately• Prior DTs strongly predict recurrence• Withdrawal severity increases with repeated episodes due to kindling• Benzodiazepines are the cornerstone—very high doses may be required• Thiamine must be given before glucose• Always search for concurrent illness such as infection, trauma, or electrolyte abnormalities
Recognize the timeline, treat early, and sedate aggressively—because in delirium tremens, rapid intervention transforms a historically lethal syndrome into a manageable medical emergency.

In this episode of Hospital Medicine Unplugged, we sprint through urticaria—recognize the wheal, distinguish acute from chronic disease, uncover autoimmune drivers, and step through a modern treatment ladder that now includes biologics and BTK inhibitors.
We start with the definition and epidemiology. Urticaria is characterized by transient pruritic wheals, angioedema, or both, typically resolving within 24 hours without scarring. While about 20% of people experience urticaria at some point in life, chronic spontaneous urticaria (CSU) affects roughly 1% of the population and disproportionately affects women aged 30–50.
The key classification hinges on duration.• Acute urticaria: symptoms lasting <6 weeks• Chronic urticaria: symptoms ≥6 weeks
Fortunately, progression from acute to chronic disease occurs in fewer than 8% of cases. Risk factors for chronicity include antithyroid antibodies and poor response to antihistamines.
Next comes an important shift in our understanding of etiology. Historically, chronic urticaria was labeled “idiopathic” in most cases. We now know that more than half of patients actually have autoimmune disease mechanisms.
Two major autoimmune endotypes exist:
Type I autoimmune (autoallergic) CSU• IgE autoantibodies against autoantigens such as thyroid peroxidase or IL-24• Leads to mast-cell activation similar to allergic disease
Type IIb autoimmune CSU• IgG autoantibodies against IgE or the FcεRI receptor• Identified in about 8–10% of patients using strict diagnostic criteria
These immune mechanisms explain why less than 35% of CSU cases truly lack detectable autoantibodies.
Diagnosis is largely clinical but follows the “7C” framework:Confirm diagnosis, identify causes, assess cofactors, evaluate comorbidities, assess consequences, evaluate biomarkers, and monitor disease course.
Routine laboratory testing should remain minimal unless clinical clues suggest otherwise. Recommended baseline tests include:• CBC with differential• ESR or CRP• TSH
Certain red flags should trigger referral or further evaluation:• Wheals lasting >24 hours• Residual hyperpigmentation after lesions resolve• Angioedema lasting several days without hives• Systemic symptoms such as fever, arthralgia, or abdominal pain
To measure disease activity, clinicians rely on validated tools.
The Urticaria Activity Score over 7 days (UAS7) is the gold standard. Patients record itch severity and hive count twice daily, producing a score from 0 to 42.
Interpretation:• 0: urticaria-free• 1–6: well controlled• 7–15: mild• 16–27: moderate• 28–42: severe
The Urticaria Control Test (UCT) is another practical tool. A score ≥12 indicates good control, while <12 suggests poorly controlled disease.
Management follows a stepwise escalation strategy.
Step 1: Second-generation H1 antihistaminesAgents include cetirizine, loratadine, fexofenadine, levocetirizine, and desloratadine, taken daily rather than as needed. About 40% of patients achieve meaningful symptom reduction with standard dosing.
Step 2: Dose escalationIf symptoms persist, antihistamine doses can be increased up to fourfold. Evidence suggests quadrupling the dose of a single antihistamine is more effective than combining multiple agents.
Step 3: OmalizumabFor antihistamine-refractory disease, omalizumab 300 mg every 4 weeks is the standard biologic therapy. Clinical trials show complete remission (UAS7 = 0) in about 36% of patients, with substantially higher response rates in real-world practice.
Patients with incomplete response may require higher doses or shorter dosing intervals.
Step 4: CyclosporineFor patients who fail omalizumab, cyclosporine (3–5 mg/kg/day) can improve symptoms in more than half of cases, although monitoring for renal toxicity and hypertension is essential.
Short courses of systemic corticosteroids (20–50 mg/day for <10 days) may help during severe flares but should never be used long-term.
The treatment landscape is expanding rapidly.
Two newly approved therapies include:
DupilumabAn IL-4 receptor α antagonist approved in 2025 for patients ≥12 years with persistent CSU despite antihistamines. Clinical trials showed complete response in about 31% of patients.
RemibrutinibA Bruton tyrosine kinase (BTK) inhibitor approved in 2025 that targets mast-cell signaling downstream of FcεRI activation. Trials demonstrated complete response rates up to ~42% with rapid onset within 2 weeks.
Another critical diagnostic consideration is urticarial vasculitis, which can mimic CSU but requires a different approach.
Key distinguishing features include:• Lesions lasting >24 hours• Pain or burning rather than itching• Residual hyperpigmentation after resolution
Systemic symptoms such as fever, arthralgia, or eye inflammation further increase suspicion. Diagnosis is confirmed by skin biopsy showing leukocytoclastic vasculitis.
Finally, we talk prognosis. Chronic spontaneous urticaria is often self-limited but unpredictable.
Remission rates:• 17% at 1 year• 45% at 5 years• 73% at 20 years
Average disease duration is 1–4 years, though relapse occurs in up to one-third of patients.
We close with the key clinical pearls:
• Chronic urticaria is rarely allergic—most cases involve autoimmune mast-cell activation• High-dose antihistamines (up to four times standard dosing) are guideline-recommended and safe• Omalizumab remains the cornerstone biologic therapy• Cyclosporine, dupilumab, and BTK inhibitors expand options for refractory disease• Always consider urticarial vasculitis when lesions last longer than 24 hours
Recognize the pattern, escalate therapy systematically, and remember—modern immunologic therapies are transforming outcomes for patients with chronic urticaria.

In this episode of Hospital Medicine Unplugged, we sprint through acute exacerbation of interstitial lung disease (AE-ILD)—recognize the sudden decline, rule out infection and cardiac causes, support oxygenation, and navigate a disease with limited treatment options and high mortality.
We begin with the diagnostic framework defined by the 2016 International Working Group. Acute exacerbation is characterized by rapid respiratory deterioration within about 1 month, accompanied by new bilateral ground-glass opacities or consolidation on CT superimposed on pre-existing fibrotic lung disease, with no evidence of cardiac failure or fluid overload. Importantly, this definition now applies across fibrosing interstitial lung diseases, not just idiopathic pulmonary fibrosis (IPF).
The critical bedside principle: AE-ILD is a diagnosis of exclusion. Infection, pulmonary embolism, pneumothorax, and heart failure must be aggressively ruled out because they can mimic exacerbations and require completely different management.
Next, we turn to pathobiology and why these patients deteriorate so rapidly. Acute exacerbations often represent diffuse alveolar damage superimposed on chronic fibrosis, producing a clinical picture similar to ARDS. However, in some non-IPF ILDs, organizing pneumonia patterns are more common—one reason those patients may respond better to immunosuppressive therapy.
Treatment remains challenging because no therapy has definitively proven benefit in randomized trials. Corticosteroids remain the most widely used intervention, but evidence is mixed.
Recent data suggest a key difference between ILD subtypes. In non-IPF ILD, higher-dose corticosteroids (>1 mg/kg prednisone equivalent) have been associated with improved survival and lower 90-day mortality. Early tapering—reducing doses by more than 10% within the first two weeks—may further improve outcomes.
In contrast, IPF exacerbations respond less predictably, and some studies suggest high-dose steroids may increase mortality, likely because the underlying pathology is often diffuse alveolar damage rather than steroid-responsive inflammation.
One therapy that should not be used is cyclophosphamide combined with steroids, which has been shown to increase mortality in acute exacerbations of IPF.
Respiratory support becomes the next critical decision point. Many patients develop severe hypoxemic respiratory failure, but outcomes with invasive mechanical ventilation are poor.
Across multiple studies:• In-hospital mortality ranges from 66–79% in ventilated ILD patients• Only ~20% of ventilated IPF patients survive to hospital discharge
Ventilator management therefore focuses on lung-protective strategies, similar to ARDS care:
• Low tidal volumes• Plateau pressures ≤30 cm H₂O• Avoid excessive PEEP, which has been associated with worse outcomes• Careful fluid management to prevent worsening pulmonary edema
Because survival after intubation is so limited, early discussions about goals of care are essential. Noninvasive ventilation or high-flow nasal oxygen may be appropriate for selected patients who decline intubation.
Prevention is therefore critically important. Antifibrotic therapies have significantly reduced exacerbation risk in IPF.
Two major agents are used:
• Nintedanib – shown in the INPULSIS trials to reduce the risk of acute exacerbations• Pirfenidone – also associated with lower exacerbation rates in multiple studies
Meta-analyses show antifibrotics reduce the risk of acute exacerbations by roughly 37%, and nintedanib has also been approved for progressive fibrosing ILDs beyond IPF, after the INBUILD trial demonstrated substantial slowing of lung function decline.
New therapies are also emerging. The FIBRONEER-ILD trial studied nerandomilast, a novel PDE-4 inhibitor, and although the composite endpoint did not reach statistical significance, the study demonstrated a meaningful reduction in mortality, suggesting a potential future role in progressive pulmonary fibrosis.
Another key strategy is early referral for lung transplantation, particularly in patients with progressive fibrotic disease. Acute exacerbations can occur unpredictably and often represent a terminal event in advanced ILD, making transplant evaluation crucial before severe deterioration occurs.
We close with the key system moves for inpatient teams:
• Recognize sudden respiratory decline in patients with fibrotic lung disease• Confirm new bilateral ground-glass opacities on CT• Aggressively rule out infection, pulmonary embolism, and heart failure• Consider corticosteroids, particularly in non-IPF ILD• Use lung-protective ventilation if respiratory failure develops• Discuss prognosis early and involve palliative care• Ensure patients with fibrotic ILD are on antifibrotic therapy when appropriate
Acute exacerbation of ILD remains one of the most devastating events in pulmonary medicine—but early recognition, careful supportive care, and preventive antifibrotic therapy can meaningfully improve outcomes.

In this episode of Hospital Medicine Unplugged, we sprint through status epilepticus—stop the seizure fast, escalate therapy on time, protect the brain, and treat the cause before refractory disease sets in.
We begin with the modern definition that changed emergency care. Status epilepticus is now defined as ≥5 minutes of continuous seizure activity or ≥2 seizures without return to baseline. The old 30-minute threshold is obsolete because neuronal injury and benzodiazepine resistance begin early, driven by GABA receptor internalization within minutes of sustained seizure activity. That’s why treatment must begin within the first 5–10 minutes.
The stakes are high: incidence is 10–40 per 100,000 annually, with 10–20% adult mortality, rising sharply in refractory cases, elderly patients, and acute symptomatic etiologies such as stroke or hypoxic injury.
Next comes the first-line intervention—benzodiazepines within 5–10 minutes. These remain Level A evidence therapy and terminate seizures in roughly 65–70% of cases when given promptly and at adequate doses.
Three effective options:• IV lorazepam 0.1 mg/kg (max 4 mg), may repeat once• IM midazolam 10 mg (0.3 mg/kg in children) — preferred if IV access unavailable• IV diazepam 0.15 mg/kg, may repeat once
The biggest real-world mistake isn’t drug choice—it’s delay and underdosing.
If seizures persist, move quickly to second-line “urgent control” therapy (10–20 minutes). The landmark ESETT trial compared levetiracetam, fosphenytoin, and valproate in benzodiazepine-refractory status epilepticus and fundamentally changed practice.
The key finding: all three drugs work equally well, stopping seizures in about 47–52% of patients.
Recommended doses:• Levetiracetam 60 mg/kg (max 4500 mg)• Fosphenytoin 20 mg PE/kg• Valproate 40 mg/kg
Because efficacy is equivalent, patient factors guide the choice:• Cardiac disease → avoid fosphenytoin (hypotension/arrhythmia risk)• Pregnancy or liver disease → avoid valproate• Simplest safety profile → levetiracetam
Other alternatives include lacosamide or phenobarbital, though ESETT drugs remain the most widely used.
When seizures continue despite these steps, the patient has entered refractory status epilepticus, which occurs in 23–43% of cases. At this stage, escalation means ICU care, intubation, and continuous EEG monitoring.
Third-line therapy involves continuous anesthetic infusions designed to suppress cortical activity:
• Propofol (20–200 mcg/kg/min) — rapid onset but risk of propofol infusion syndrome with prolonged use• Midazolam infusion — commonly used but tachyphylaxis develops• Pentobarbital coma — powerful seizure suppression but high rates of hypotension and prolonged sedation
Most modern practice favors propofol or midazolam over barbiturate coma.
A newer strategy gaining traction is ketamine, an NMDA receptor antagonist with a completely different mechanism from GABAergic drugs. Unlike other anesthetics, ketamine preserves blood pressure and respiratory drive, making it a useful adjunct in refractory disease.
If seizures continue ≥24 hours despite anesthetic therapy, the condition becomes super-refractory status epilepticus, a devastating scenario with mortality approaching 40–50%.
Management expands to include:• Ketamine infusions• Immunotherapy (steroids, IVIG, plasmapheresis) when autoimmune etiologies are suspected• Ketogenic diet• Neuromodulation or epilepsy surgery in select cases
Two particularly challenging syndromes fall into this category:NORSE (New Onset Refractory Status Epilepticus) and FIRES (Febrile Infection-Related Epilepsy Syndrome), often requiring aggressive immunologic treatment.
Throughout all stages, clinicians must identify and treat the underlying cause—the strongest determinant of outcome.
Prognosis varies dramatically depending on response to therapy:• Benzodiazepine-responsive SE: <5% mortality• Second-line responsive SE: ~10–15% mortality• Refractory SE: 20–40% mortality• Super-refractory SE: up to 50% mortality
Poor outcomes are associated with older age, acute symptomatic etiologies (stroke, infection, hypoxic injury), prolonged seizures, and nonconvulsive status epilepticus with coma, which is one of the strongest predictors of mortality.
Finally, systems matter. Hospitals that implement structured status epilepticus protocols dramatically improve outcomes. Protocol adherence reduces time to second-line therapy from nearly an hour to about 20 minutes and lowers ICU transfer rates.
We close with the practical escalation algorithm every inpatient team should know:
• 0–5 minutes: ABCs, glucose check, IV access, prepare meds• 5–10 minutes: benzodiazepine (lorazepam, midazolam, or diazepam)• 10–20 minutes: second-line AED (levetiracetam, fosphenytoin, or valproate)• 20–40 minutes: prepare for intubation, initiate EEG monitoring• Refractory SE: continuous anesthetic infusion in the ICU• Super-refractory SE: ketamine, immunotherapy, ketogenic diet, or surgical options
Treat fast, escalate early, follow the algorithm, and search relentlessly for the underlying cause. In status epilepticus, every minute of uncontrolled seizure activity threatens the brain.